Executive Summary

On 2026-09-16, Krsnaa Diagnostics executed a definitive 15-year Concession Agreement with the Government of Punjab for establishing 4 PET-CT diagnostic centers under a DBFOT model. While this represents a high-margin clinical expansion into oncology, the project is small relative to Krsnaa's ₹816 Cr TTM revenue base (~2.5% steady-state revenue contribution). Under Rule 4, Krsnaa's low promoter holding (27.11%) strictly caps the verdict at POSSIBLE and confidence at 0.45.

1. Ramp-Aware Catalyst & Financial Math

• Capex Requirement: A medical-grade PET-CT scanner along with radiation-shielded bunker site preparation costs ~₹8.5–11.0 Cr per site. Total capex for 4 installations will range between ₹35 Cr and ₹44 Cr.
• Execution Timeline: Setting up nuclear medicine/oncology centers requires AERB clearances and medical physicist staffing, implying a 12 to 18-month commercialization gestation.
• Steady-State Revenue Output: Assuming 10 to 12 patient scans per day per facility across 310 operational days at an average PPP subsidized cash tariff of ~₹11,000 per scan, each center yields ~₹3.5–4.1 Cr annually. For 4 centers, aggregate steady-state revenue is estimated at ₹15–18 Cr/year (up to ₹20 Cr at peak scan volumes), representing a 2.0% to 2.5% expansion over TTM revenue.
• Earnings Conversion: At steady-state, specialized imaging yields ~30% EBITDA (~₹5.5 Cr). Deducting straight-line depreciation of ~₹4.0 Cr/year (over 10 years) and interest on project debt (~₹1.5 Cr), incremental PAT will be modest at ~₹0.8–1.5 Cr (~₹0.25 to ₹0.45 EPS uplift).

2. Industry Dynamics & Capital Intensity

• Capital Intensity: HIGH. Nuclear diagnostics involve imported imaging hardware and rigid reliance on short-lived radioisotopes (18F-FDG has a 110-minute half-life), necessitating precise daily logistic coordination.
• Industry Growth: The broader Indian diagnostic sector exhibits 11-14% CAGR, with oncology PET-CT diagnostic segments growing at 15-18% due to rising cancer screening rates.

3. Fundamental Quality & SEPA Grade (Grade: C)

• Operating Performance: FY26 demonstrated revenue of ₹773 Cr with 27.4% OPM and ₹101.7 Cr PAT. However, Q1 FY27 results highlighted severe vulnerability: while revenue expanded 22% YoY to ₹235.5 Cr via Rajasthan project initialization, PAT contracted 19.3% YoY to ₹16.6 Cr from margin dilution, higher financing charges, and hospital fee sharing.
• Capital Return & Leverage: ROCE stands at 13.0%, suppressed by the heavy asset footprint of PPP tenders. Total debt stands at ₹531 Cr (D/E 0.54) with ₹992 Cr net worth.
• Working Capital Stress: PPP contracts carry high receivable risks, with Himachal Pradesh and Karnataka debtor cycles exceeding 125 days.

4. Valuation & Scenario Calibration

• Current Profile: Stock trades at ₹536.4, 17.8x TTM EPS of ₹30.06. While peer diagnostics trade at a median P/E of 58.9x, Krsnaa trades at a persistent structural discount due to public-tender counterparty risks and low ROCE.
• Base Case (+25%, Target ₹670): 18-36 month horizon. Rajasthan and Punjab projects commission smoothly; revenue grows at 15% CAGR to ~₹1,080 Cr by FY28; operating margins stabilize at 26%, generating PAT of ~₹110 Cr (EPS ~₹33.5). Target multiple re-rates moderately to 20x.
• Bull Case (+55%, Target ₹830): Retail diagnostic revenue reaches the targeted 20% share, improving working capital; Punjab PET-CT units achieve high capacity utilization; ROCE crosses 16%; P/E expands to 22x on FY28 EPS of ₹38.
• Bear Case (-25%, Target ₹400): Further receivables write-offs/provisions in state contracts; ₹62.69 Cr income tax demand materializes adversely; OPM settles near 23%; P/E derates to 14x on depressed PAT of ₹85 Cr.

5. Verdict Rationale

The 4 PET-CT concession is commercially attractive as it uses a direct cash user-fee collection model, bypassing government debtor delay. However, with promoter ownership stagnant at 27.11%, active tax disputes of ₹62.7 Cr, and weak 13% ROCE, the structural hurdles prevent a high-conviction classification.

Executive Summary

Krsnaa Diagnostics (KRSNAA) reported Q1 FY27 consolidated revenue of ₹235.5 Cr (+22% YoY), driven by the operationalization of its Rajasthan pathology network (contributing ₹25.7 Cr in Q1). However, Net Profit (PAT) declined 19.3% YoY to ₹16.6 Cr due to upfront fixed infrastructure costs, higher hospital revenue share expenses, and a doubling of finance costs (₹14.8 Cr). Concurrently, the Board approved a ₹91.6 Cr preferential warrant issue to promoters at ₹565 per share.

1. Industry Context & Capital Intensity

• Industry Structure: Diagnostic healthcare in India grows at a 12-14% CAGR, shifting towards organized players and integrated radiology + pathology service delivery.
• Capital Intensity: Medium to High. Radiology equipment (CT/MRI scanners) requires significant upfront capex, which drives up interest and depreciation costs until utilization matures.
• Execution Difficulty: PPP contracts require setting up centers inside government medical institutions across multiple districts, making rollout logistically complex.

2. Ramp-Aware Catalyst & Financial Impact Analysis

• Rajasthan Project: 31 mother labs, 62 hub labs, and 1,228 collection centers are live, adding ~₹100 Cr in annual revenue (~13% of TTM revenue).
• Revenue Impact: Q1 revenue reached ₹235.5 Cr. Annualized FY27 revenue is projected at ₹950 Cr - ₹980 Cr (+23-26% YoY growth).
• Profitability Impact: Near-term PAT is dampened by initial operating expenses and finance costs. As volume density scales across Rajasthan centers, operating leverage should restore OPM towards 26-27% in FY28.
• Promoter Warrants: Influx of ₹91.6 Cr via warrants at ₹565 per share will partially deleverage the balance sheet (Debt: ₹531 Cr) and lower interest costs.

3. Multibagger Quality & Governance Evaluation

• ROCE: 13.0%, suppressed by heavy capital expenditure in PPP equipment prior to peak utilization.
• Promoter Holding: 27.11%. Per research guardrails, promoter holding < 35% caps the verdict at POSSIBLE and confidence at <= 0.50.
• Receivables Risk: High dependency on state governments; receivables in Himachal Pradesh and Karnataka remain a key liquidity risk.

4. Valuation & Peer Comparison

• Valuation: Trailing P/E is 17.8x against a peer median trailing P/E of 48.5x. P/B is 1.8x.
• Re-rating Potential: While the trailing P/E looks cheap relative to retail diagnostic peers (Lal PathLabs, Metropolis), the discount reflects PPP execution risks, lower gross margins, and lower promoter skin in the game.

5. Calibrated Scenarios (18-36 Month Horizon)

• Bull Case (+70%, Target Price ₹946): Rajasthan reaches full capacity, retail segment grows to >20% of revenue, OPM expands to 28%, and P/E re-rates to 25x on FY28 EPS of ₹38.
• Base Case (+35%, Target Price ₹750): Steady execution of PPP contracts, PAT recovers to ₹120-130 Cr in FY28, valuation re-rates moderately to 20x P/E.
• Bear Case (-25%, Target Price ₹418): Government receivables stretch further, margin compression persists from high debt/interest expenses, P/E de-rates to 13x.

6. Verdict Rationale

While top-line growth is robust (+22% YoY) and the promoter warrant issue provides growth capital, the sub-35% promoter holding (27.11%), moderate ROCE (13%), near-term PAT drop (-19%), and government payment risks restrict the verdict to POSSIBLE with a confidence score of 0.45.

Investment Thesis & Catalyst Analysis: Krsnaa Diagnostics Ltd. (KRSNAA)

Analysis Date: July 23, 2026 Current Price: ₹536.4 | Market Cap: ₹1,743 Cr | TTM P/E: 17.1x

1. Catalyst Evaluation & Ramp-Aware Impact Math

On July 23, 2026, Krsnaa Diagnostics announced a significant expansion in Himachal Pradesh (HP) under a new 7-year Public-Private Partnership (PPP) agreement (extendable by 3 years). The contract expands their CT scan footprint in HP from 12 to 34 centers (+22 centers).

• Capacity Expansion: Represents a ~11.8% increase over Krsnaa's total CT/MRI fleet of 186 centers.
• Operational Shift: Crucially, the new agreement operates on a majority cash basis, directly tackling the historical bottleneck of stretched government receivables in Himachal Pradesh.

Financial Ramp Math:

• TTM Base Revenue: ₹773 Cr
• Estimated Revenue per CT Center: ~₹3.2 - ₹3.5 Cr/year at optimal maturity.
• Incremental Revenue Potential (22 centers): ~₹70 - ₹77 Cr steady-state annual revenue.
• Ramp Schedule:
• Year 1 (FY27): ~10-12 centers operationalized mid-year -> ~₹35 Cr revenue uplift (+4.5% over TTM revenue).
• Steady-State (FY28+): All 22 centers operational -> ~₹73 Cr annual revenue uplift (+9.5% over TTM revenue).
• PAT & EPS Impact:
• Current TTM PAT is reported at ₹102 Cr, but Q4 FY26 PAT included a one-off fair valuation gain of ₹22.18 Cr. Core normalized TTM PAT is ~₹80 Cr (Normalized EPS: ~₹24.6).
• At steady-state incremental revenue of ₹73 Cr with a core NPM of ~12% (benefiting from cash collection efficiency), incremental PAT contribution will be ~₹8.8 Cr.
• This yields a normalized steady-state EPS uplift of +11.0%.

2. Industry Capital Intensity & Quality Assessment

• Industry Context: Diagnostic radiology is capital-intensive requiring upfront import/lease of high-end equipment (CT/MRI machines). Expected healthcare diagnostic industry CAGR is 12-15%.
• ROCE & Balance Sheet: KRSNAA's ROCE stands at 13.0%, suppressed by capital expenditure cycles and government debtor days. Total debt is ₹531 Cr with D/E of 0.54.
• Quality Gate Verdict: Fails strict quality threshold (ROCE 13% < 15%), but the transition to cash-basis B2G contracts mitigates working capital drag.

3. Governance & Structural Guardrails (Mandatory Binding Caps)

• Promoter Shareholding: 27.11% (Well below the 35% safety threshold).
• Impact on Thesis: Under strict research guardrails, a promoter stake below 35% automatically caps the overall Multibagger Verdict at POSSIBLE and Confidence at <= 0.5, reflecting potential dilution risk and vulnerable corporate governance structure.
• Executive Leadership: Recent overhaul in April 2026 including an Interim CFO appointment adds transition risks.

4. Valuation Context & Peer Comparison

• Current P/E: 17.1x TTM reported earnings (or ~21.8x normalized earnings).
• Peer Median P/E: 66.5x (e.g., Lal PathLabs, Metropolis, Fortis, Medanta).
• Re-rating Potential: KRSNAA trades at a deep structural discount due to its B2G PPP tilt and past working capital issues. If cash collection improves via this HP contract template, P/E multiple expansion toward 25-30x is feasible.

5. Scenario Analysis & Price Targets (18-24 Month Horizon)

• Bull Case (₹885 / +65%):
• Successful rollout of all 22 centers in HP within 12 months on cash basis.
• Core PAT grows to ₹115 Cr as retail mix reaches target 20%.

• Re-rating to 24x P/E on normalized EPS.

• Base Case (₹724 / +35%):

• 22 centers commissioned over 18 months; core PAT reaches ₹100 Cr.

• P/E re-rates modestly to 22.5x base earnings.

• Bear Case (₹402 / -25%):

• Delays in site handovers in HP; persistent receivables lock-up in other states (Karnataka).
• Core PAT stagnates around ₹80 Cr; P/E decompresses to 15x.

6. Final Verdict Rationale

While the HP PPP expansion is high quality (cash model + 11.8% radiology fleet addition), the stock's multibagger potential is constrained by low promoter skin-in-the-game (27.11%) and one-off fair value gains inflating reported TTM figures. The verdict is capped at POSSIBLE with a score of 48/100.